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Abstract. To detect congenital ZIKV infection (CZI) in a birth cohort and among high-risk neonates in Vietnam, we
collected umbilical cord blood plasma samples of newly delivered babies and peripheral plasma samples of high-risk
neonates in Nha Trang, central Vietnam, between July 2017 andSeptember 2018. Sampleswere subjected to serological
and molecular tests. Of the 2013 newly delivered babies, 21 (1%) were positive for Zika virus (ZIKV) IgM and 1,599 (79%)
for Flavivirus IgG. Among the 21 ZIKV IgM-positives, 11 were confirmed to have CZI because their plasma samples had
anti-ZIKV neutralization titers ³ 4 times higher than those against dengue virus (DENV)-1 to 4 and Japanese encephalitis
virus (JEV) and were tested for the ZIKV RNA positive by real-time reverse transcription–PCR. Therefore, the incidence of
CZI in our birth cohort was approximately 0.5%. Of the 150 high-risk neonates, three (2%) and 95 (63%) were positive for
ZIKV IgM and Flavivirus IgG antibodies, respectively. None of the three ZIKV IgM-positives had ³ 4 times higher anti-ZIKV
neutralization titers than those against DENV-1 to 4 and JEV, andwere therefore considered as probable CZI. Our results
indicate that CZI is not rare in Vietnam.Although thosewith confirmedCZI did not showapparent symptoms suspectedof
congenital Zika syndrome at birth, detailed examinations and follow-up studies are needed to clarify the CZI impact in
Vietnam. This is the first report of CZI cases in a birth cohort in Asia.
INTRODUCTION
Zika virus (ZIKV) of the family Flaviviridae, genus Flavivirus
can be transmitted to humans through the vector Aedes
mosquitoesor throughnonvector transmission suchas sexual
contact, maternal–fetal transmission, and blood transfusions.1–5
The first humancaseof ZIKV infectionwas reported in 1954 in
Nigeria, and sporadic cases have been noted in Asia.6,7 It has
been widely reported that approximately 80% of people with
ZIKV infection are asymptomatic.8,9 Although the disease is
self-limiting, cases of neurological manifestations have been
described. Between 2015 and 2016, ZIKV had been of global
health concern following large outbreaks in the Americas and
the observed associated congenital abnormalities, including
microcephaly, intrauterine growth restriction, blindness, and
stillbirth.10 Despite a long period of ZIKV circulation in Asia,
only three confirmed cases of congenital ZIKV infection (CZI)
with microcephaly were reported in this region: two in Thai-
land and one in Vietnam.11,12 In Vietnam, 219 and 13 cases of
ZIKV disease were reported in 2016 and 2017 (January–
February), respectively.13 No data are available on the in-
cidence and embryotoxicity of CZI in a birth cohort in Asia.
We herein report data of ZIKV infection from 1) a large-scale
birth cohort study on mother-to-child infections and 2) in-
vestigation of neonates who were suspected with congenital
infection in Vietnam.
MATERIALS AND METHODS
Study participants and sample collection. The present
study was conducted in Khanh HoaGeneral Hospital (KHGH),
Nha Trang, Vietnam, from July 2017 to September 2018, and
consisted of two parts. For the first part of the study, we en-
rolled all women who 1) delivered their babies at KHGH, 2)
were 18 years or older at the time of delivery, and 3) resided in
selected 16 communes in Nha Trang, during the study period.
Exclusion criteria for this part of the study were women who
had 1) spontaneous/induced abortions or stillbirths, 2) multi-
ple pregnancies, or 3) serious complication from/during this
pregnancy. Blood samples were collected from umbilical
cords of babies just after their delivery at the obstetrics ward.
ethylenediaminetetraacetic acid-treated tubes were used for
blood collection. Plasma was separated by centrifugation
(3,000 rpm × 10 minutes) and kept in a −80C freezer until
testing.
For the secondpart of the study, during the studyperiod,we
enrolled high-risk neonates (children aged 28 days or less) 1)
born at KHGH from women who had any two disease
symptoms such as fever, rash, arthralgia/arthritis, lymph-
adenopathy, and conjunctivitis, or 2) born at KHGH or re-
ferred to neonate intensive care unit/pediatric department in
KHGH and who had any symptoms related to congenital
infection such as suspected meningoencephalitis, micro-
cephaly, hydrocephalus, glaucoma, cataract, thrombocyto-
penia, purpura, hearing impairment, and lymphadenopathy,
or who had head circumference of < 30 cm at birth, and
whose birth weight for gestation age was equal or below the
cutoff on birth weight patterns by gestation age reference
setting.14,15 Exclusion criteria for the second part were ne-
onates with confirmed chromosomal abnormality or those
with well-known congenital syndrome related to a genetic
defect. Some of the participants in the second part of the
study could also be included in the first part if their mothers
lived in the catchment area and delivered them at KHGH
during the study period. Peripheral blood samples were
collected from the neonates, and the plasma was separated
and kept as earlier.
Written informed consents were obtained from mothers for
their participation in the first part of the study aswell as for their
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babies’ participation in the first and/or second parts of the
study.
This work was approved by the Ethics Committees of the
Institute of Tropical Medicine, Nagasaki University, Japan
(160908158), and the National Institute of Hygiene and Epi-
demiology, Hanoi, Vietnam (IRB-VN01057-30/2015).
Viruses and cell lines. The virus strains used for the sero-
logical tests, namely, IgM capture ELISA, Flavi IgG ELISA, and
neutralization tests, were as follows: MR 766 (ZIKV), 99St12A
(dengue virus [DENV]-1), 00st22A (DENV-2), SLMC50 (DENV-
3), SLMC318 (DENV-4), andJaOrS982 (Japanese encephalitis
virus [JEV]). These viruses were propagated in C6/36 Aedes
albopictusmosquito cells andwere used to inoculate the Vero
(Africangreenmonkeykidneyepithelial cell lineATCC,CCL81)
cell line for virus titration and neutralization tests.
IgM capture ELISAs for the detection of ZIKV, DENV,
and JEV infections. In-house IgM capture ELISAs were car-
ried out using the protocol described previously with minor
modifications.16 Each well of 96-well microplates (Maxisorp,
Nalge Nunc International, Roskilde, Denmark) was coated
with 100 μL (5.5 μg/100 μL) of antihuman IgM goat IgG anti-
body (Cappel ICN Pharmaceuticals, Aurora, OH) in ELISA
coating buffer (0.05 M carbonate–bicarbonate buffer, pH 9.6,
containing 0.0% sodium azide). Plates were then incubated at
37C for 1hour or at 4Covernight. Eachwellwasblockedwith
100 μL of BlockAce (UK-1 B 80, Yukijirushi, Sapporo, Japan),
except for the blank wells, and plates were incubated at room
temperature for 1 hour. After incubation, wells were washed
three times with phosphate-buffered saline (PBS) without
calciumandmagnesiumbut containing 0.1%Tween 20 (PBS-
Tween 20 [PBS-T]). Test samples, as well as positive and
negative control samples, were diluted at 1:100 in PBS-T, and
100 μL aliquots of these samples were distributed into dupli-
cate wells. Plates were incubated at 37C for 1 hour and then
washed as described earlier. Zika virus or tetravalent DENV
or JEV antigen (128 ELISA units) at 100 μL/well was added
after which the plates were incubated at 37C for 1 hour.
After washing as described earlier, horseradish peroxidase
(HRP)-conjugated anti-Flavivirusmousemonoclonal antibody
(12D11/7E8) at 1:1,000dilution for anti-ZIKV IgMcaptureELISA,
or 1:1,500 dilution for anti-DENV or anti-JEV IgM capture ELISA
was added at 100 μL/well. Plates were incubated at 37C for 1
hour and washed as earlier. Color was developed by adding in
each well a 100-μL volume of 5 mg o-phenylenediamine dihy-
drochloride (OPD) (Sigma Chemical, St. Louis, MO) with 0.0%
hydrogen peroxide in 10 mL of 0.05 M citrate phosphate buffer,
pH 5.0. Plateswere kept at room temperature for 30–60minutes
in a dark place. To terminate the reaction, 100 μL of 1 N sulfuric
acid was added to each well, and then the optical density (OD)
was read at 492 nm (Multiscan JX, model no. 353; Thermolab
System, Tokyo, Japan). A positive control (or test sample)/
negative control OD ratio greater than or equal to 2.0 was con-
sidered positive.
Anti-Flavivirus IgG ELISA. In-house indirect IgG ELISA
was performed to detect the presence of anti-Flavivirus IgG in
plasma samples, and a purified JEV was used as assay anti-
gen.17 In the procedure, all wells of the 96-well microplates,
except for the blanks, were coated with 100 μL of JEV antigen
(250 ng/100 μL/well) diluted with ELISA-coating buffer. Plates
were incubated at 37C for 1 hour or at 4Covernight. All wells
except for the blanks were blocked with 100 μL of the original
concentration of BlockAce and were incubated at room
temperature for 1 hour. Plates were washed three times with
PBS-T, after which 100 μL of each test plasma sample diluted
at 1:1,000 in PBS-T + 10% BlockAce was added in duplicate
wells in each plate. Control sample known to contain the anti-
body to test antigenwas run on each plate as a positive control.
After incubation at 37C for 1 hour, plates were washed,
and 1:30,000 diluted HRP-conjugated antihuman IgG goat
IgG (American Qualex, San Clemente, CA) in PBS-T + 10%
BlockAce was added at 100 μL/well. Plates were incubated at
37C for 1 hour, followed by washing. Initiation of the peroxi-
dase reactionwas performedby the addition of OPDsubstrate
solution (described earlier) at 100μL/well. Plateswere incubated
at room temperature for 30–60minutes in the dark, and then the
reaction was stopped by the addition of 1 N sulfuric acid at 100
μL/well. A standard curve was prepared by using the OD492
values of the positive control serum starting with a 1,000-fold
dilution, followed by serial 2-fold dilutions up to 1:212 in PBS-T +
10% BlockAce. IgG titers of test serum samples were de-
termined fromthepositivestandardcurve.Asample titerequal to
or greater than 1:3,000 was considered to be positive.
Focus reduction neutralization test. To confirm the status
of ZIKV infection in the study subjects, plasma samples were
checked for the ability to neutralize ZIKV, the four serotypes of
DENV, and JEV by 50% focus reduction neutralization test
(FRNT50).
16,18 Plasma samples were heat-treated at 56C for
30 minutes and diluted serially. Serially diluted samples at
150-μL volumes were mixed with equal volumes of specific
virus at 60 focus-forming units, and mixtures were incubated
at 37C for 1 hour for virus–antibody neutralization reaction.
Each mixture was inoculated onto Vero cell monolayer in 96-
well plates. After incubation at 37C for 1 hour, the infected
cells were overlaid with 1.3% methylcellulose 4,000 in 2%
fetal calf serum minimum essential media. The plates with
ZIKV or JEV were then incubated at 37C for 2 days, and the
plates with DENV were incubated for 3 days in the same
temperature. The plates were washed with PBS (−). Cells in
each plate were fixed with 4% paraformaldehyde phosphate-
buffered solution for 30 minutes at room temperature, rinsed,
andwere permeabilized with 1%NP-40 solution in PBS (−) for
30 minutes at room temperature. After washing, the plates
were blocked with BlockAce for 30 minutes at room temper-
ature. Pooled human serum samples with a high titer of anti-
Flavivirus IgG (diluted 1:1,500) were then added per well;
plates were then incubated at 37C for 1 hour and washed.
Subsequently, 1:1,000 diluted HRP-conjugated goat antihu-
man IgG was added to each well, after which plates were
incubated at 37C for 1 hour. Staining of positive cells was
visualizedby the addition of a 0.5-mg/mL solution of substrate
3, 39-diaminobenzidine tetrahydrochloride in PBS (−) with
0.0% of H2O2 at room temperature. Staining reaction was
allowed to proceed for 10 minutes, after which the cells were
washed. The number of foci of stained cells per well was
counted under a microscope. The reciprocal of the endpoint
serum dilution that provided a 50% or greater reduction in the
meannumber of foci relative to thecontrolwells that contained
no serum was considered to be the FRNT50 titer. The volume
used for all the reactants in this test was at 100 μL/well.
Conventional and real-time reverse transcription–PCR
(qRT-PCR) for ZIKV. Viral RNA was directly extracted from
plasmabyusingViral RNAMini Kit (QIAGEN,Hilden,Germany)
according to the manufacturer’s instructions. The qRT-PCR
wasperformedbyusingTaqManFast Virus 1-StepMasterMix
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kit (Applied Biosystems, Foster City, CA) following the pro-
tocol from a previous report with three primer sets for ZIKVE
and NS5 genes.19–23 Cycle threshold value < 40 was consid-
ered as ZIKV positive for qRT-PCR. Standard complementary
DNA at 10-fold serial dilutions (108–102 genome copies) was
applied for quantification of viral genome levels.20 The viral
genome levels were expressed as log10 genome copies/mL.
Conventional RT-PCR was performed by using Prime Script
one step RT-PCR Kit (Takara Bio Inc., Shiga, Japan) following
the manufacturer’s instructions and using previously pub-
lished primers for ZIKVNS3 gene.24
Zika virus case classification.We regarded a case as CZI
if ZIKVRNAwasdetected in thecordor neonatal bloodplasma
or if the neonate was ZIKV IgM positive and positive for neu-
tralization test only against ZIKV but not with other flaviviruses
or when the neutralizing antibody titer against ZIKV was ³ 4
times higher than the antibody titers against other flaviviruses.
This definition is consistent with confirmed ZIKV infection in
the WHO criteria.25 The WHO defined a ZIKV infection as a
probable case if the clinical sample is positive for IgMantibody
against ZIKV and the ratio of ZIKV neutralization titer to other
Flavivirus neutralization titers is less than 4 and with no ZIKV
RNA detected by RT-PCR.25 In case there is no adequate
plasma sample for the performance of RT-PCR, we also
considered infection as probable. In this study, we called our
probable case as probable CZI and regarded it as non-
confirmed CZI.
RESULTS
In total, 2015 mothers, who were about to give birth, were
enrolled in the first part of the study, and a total of 2013 um-
bilical cord plasma samples from their newly born babieswere
analyzed. In the second part of the study, 150 neonates were
enrolled, and their plasma samples were also analyzed. In the
first part of the study, 21 (1%) of the 2013 newly born babies
were positive for ZIKV IgM, seven (0.3%) for DENV IgM, and
1,597 (79.3%) for Flavivirus IgG (Table 1). Among the 21 ZIKV
IgM-positives, nine were positive for JEV and/or DENV IgM. In
the second part of the study, of the 150 neonates, three (2%),
two (1.3%), and 95 (63.3%) were positive for ZIKV IgM, DENV
IgM, and Flavivirus IgG, respectively (Table 1). Of the three
ZIKV IgM-positives, one was JEV IgM positive.
Among the 21 ZIKV IgM-positive newly born babies, 11 had
anti-ZIKV neutralization titers ³ 4 times higher the neutraliza-
tion titers against DENV-1 to 4 and JEV (Table 2). Therefore, 11
(0.5%) in the birth cohort were confirmed as CZI. In addition,
their samples had ZIKV IgM P/N ratios higher than those for
DENV and JEV. Six of the 11 babies had plasma ZIKV RNAs
that were positive in the real-time PCR in the two primer sets
used in the study, whereas five were positive in one of the two
primer sets. However, detection of their ZIKV RNAs by con-
ventional RT-PCRshowed negative results. The other 10 of 21
ZIKV IgM-positives had cord blood plasma samples with anti-
ZIKV neutralization titers < 4 times than those against DENV-1
to 4 and JEV, and thus were considered to have proba-
ble CZI.
The three ZIKV IgM-positive neonates in the second part of
the study had plasma samples with anti-ZIKV neutralization
titers < 4 times than those against DENV-1 to 4 and JEV. They
were considered as probable CZI and hence were not con-
firmed CZI. With regard to annual and seasonal patterns for
CZI, therewere nine confirmedcases ofCZI in July–November
2017 and two in July–September 2018, suggesting annual
variability and seasonality. Our findings showed approxi-
mately 0.5% incidence ofCZI, or 5.5 per 1,000 live births in our
birth cohort study in central Vietnam.
Among the 11 confirmed CZI cases, nine babies did not
show any apparent symptoms at birth and were discharged
together with their mothers after 5 days as usual delivery
hospitalization. One baby girl who showed symptoms of ill-
ness vomited repeatedly and did not suck hermother’s breast
milk on the next day after birth. Her white blood cell count was
20,110/μL (neutrophil 67.7%). She was hospitalized in the
pediatric ward, treated with antibiotics for neonatal infection,
and given phototherapy for neonatal jaundice. She was dis-
chargedafter 5daysof hospitalization. Theother babygirl who
showed symptoms of illness was born to a mother who had
pre-labor rupture of membranes. The baby, too, had vomited
and could not be breastfed. Her white blood cell count was
28,300/μL (neutrophil 71.0%) on the day of birth. She was
treated with antibiotics for neonatal bacterial infection and
had phototherapy for neonatal jaundice at the pediatric de-
partment for 11 days. After getting well, she was discharged.
These two baby girls did not show any symptoms suspected
as congenital infection as listed in the inclusion criteria for the
second part of the study, and they were not enrolled in the
second part. The 10 caseswith probable CZI in the first part of
the study had no apparent symptoms at birth.
DISCUSSION
In this study, we reported the occurrence of CZI among
babies delivered in Nha Trang, Vietnam. Their infections were
confirmed based on the positive detection of ZIKV RNA, IgM
against ZIKV, and neutralizing antibodies against ZIKV by
using their cordbloodplasmasamples. Itwasnoted that these
samples had positive results for IgM and/or neutralization
activity against more than one virus. This could be because
of cross-reaction of the tested antibodies against ZIKV,
DENV, and JEV, all of which belong to the same Flaviviridae
family.26–28 High percentage of cord blood and neonate
plasma samples positive for anti-Flavivirus IgGwas observed,
and it could be because of the passively transferred maternal
IgG.29 Increasing number of divergent ZIKV strains that high-
light genetic variability is regarded as a potential limiting factor
TABLE 1
Positive rates of ZIKV IgM, DENV IgM, and Flavivirus IgG in pregnant women and neonates, Nha Trang, Vietnam, July 2017–September 2018
Source of samples Total no. of samples
ELISA-positive samples
ZIKV IgM DENV IgM Flavi IgG
Cord blood plasma in the birth cohort 2,013 21 (1.0%) 7 (0.3%) 1,597 (79.3%)
Plasma from high-risk neonates 150 3 (2.0%) 2 (1.3%) 95 (63.3%)
DENV = dengue virus; ZIKV = Zika virus.
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of the sensitivity of ZIKVqRT-PCRbaseddiagnosis; therefore,
a previous study suggested to use several qRT-PCR targets
for diagnosis.23 The 11 babieswith confirmedCZI in this study
had their plasma samples positive for qRT-PCR in at least one
primer set. However, conventional PCR performed to plasma
positives by qRT-PCR showed negative results which could
be because of low viral loads in the plasma. Previous studies
reported that conventional RT-PCR could detect ZIKV viral
load in most of the samples, with an estimated 106–1010 RNA
copies/mL.23,30
Published studies showed strong association between
microcephaly and ZIKV infection confirmed by qRT-PCR,
capture IgM ELISA, or both.21,31,32 In Brazil, 32 of 91 neonates
born with microcephaly were confirmed positive for ZIKV in-
fection by qRT-PCR or anti-ZIKV IgMELISAwith confirmation
more frequent in cerebrospinal fluid than in serum.33 Also in
Brazil, another study reported that levels of ZIKV IgM and
neutralizing antibodies were higher in babies with micro-
cephaly cases than in the neonate controls (at the time of birth)
and their mothers.34 In our study, we confirmed CZI in 0.5%
(11/2013) of newly born babies based on the results of IgM
capture ELISA, qRT-PCR, and neutralization test by using
their cord blood samples. Comparing our data from the
Americas where the rate of microcephaly/CZI varies from 5%
to 14%,35,36 our study showed a low rate of CZI infection, and
it could be associated with the differences in the character-
istics of the ZIKV belonging to the different clades of Asian
lineage. A previous study on the importation of ZIKV from
Vietnam to Japan in 2016 indicated that the isolated virus
belonged to the Southeast Asian clade of the Asian lineage,
and it was distinct from the ZIKV isolates (American clade of
Asian lineage) in the Americas.37 Other reports suggested
that Southeast Asian clade of ZIKV had lower replicative
ability than the American clade of Asian lineage/African
lineage.38
This is the first report of ZIKV infection in a birth cohort in
Asia. Our results indicate that CZI is not rare in Vietnam. Even
though eye examinations and brain imaging were not con-
ducted in this study, all the infected babies did not show ap-
parent symptoms suspected of congenital Zika syndrome,
which are characterized by severe microcephaly (in which the
skull has partially collapsed), decreased brain tissue with a
specific pattern of brain damage, damage to the back of the
eye, congenital contractures, and hypertonia restricting body
movement soon after birth.39,40 Newbornswhosemothers are
infected with ZIKV during pregnancy have a 5–14% risk of
congenital Zika syndromeanda4–6%risk of ZIKV-associated
microcephaly,35,36,41–46 whereas a study involving pregnant
women fromRio de Janeiro used abroader definition for ZIKV-
associated outcomes and identified adverse outcomes in
42% of fetuses and infants exposed to the virus.41 Thus, gen-
erally, the number of children who were born to mothers with
ZIKV infection during pregnancy but who did not have apparent
disability at birth is large, and our findings are in agreement with
that. However, a previous study found that infants with in utero
ZIKV exposure without congenital Zika syndrome appeared at
risk for abnormal neurodevelopmental outcomes in the first
18 months of life.39 Therefore, detailed clinical assessment
combined with ophthalmologic examination, hearing screening,
and brain imaging, and long-term follow-up including neuro-
developmental surveillance of infected offspring are needed to
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